cosedimented between 1.15 and 1.25 g/ml in sucrose gradients. Moreover, the mAb D32.10 detected E1E2 by immunostaining in HCV-infected hepatocytes in parallel with E2 and core antigens. Conclusion: Our results provide evidence that the mAb D32.10 recognizes E1E2 envelope complexes expressed in the cell cytoplasm and on the surface of HCV RNAcontaining particles released from short-term cultures of in vivo infected hepatocytes.
Introduction
Hepatitis C virus (HCV) is a positive-strand RNA virus that belongs to the genus Hepacivirus of the Flaviviridae family. This virus exhibits a narrow host (humans and chimpanzees) and tissue (hepatocytes) tropism. HCV is the most common blood-borne virus which causes chronic infections in approximately 170 million people in the world. Chronic hepatitis may progress to liver cirrhosis and hepatocellular carcinoma. Current therapies are limited, and only effective in 50% of infected patients depending on the genotype. a vaccine has been hampered by the difficulties to infect primary cultures of human hepatocytes by HCV-positive serum [2, 3] .
In the last decade, significant progress has been made with the development of several HCV models: HCV-like particles produced in insect cells [4] , HCV pseudotyped particles displaying E1 and E2 glycoproteins onto retroviral and lentiviral core particles [5] , and cell culturegrown HCV (HCVcc) obtained after transfection of a unique HCV genotype 2a complete replicon (JFH-1) into Huh-7 or Huh7-derived hepatoma cells [6] [7] [8] . However, despite its strong advantages, the HCVcc model tightly depends on the JFH-1 nonstructural genes (replicase complex) of genotype 2a and the poor innate immune response characteristic of immortalized Huh-7 or Huh-7-derived cells [9] .
We have recently reported the feasibility of primary cultures of HCV-infected human hepatocytes from cirrhotic livers removed at transplantation, and demonstrated that the morphological and functional properties of this system provide unique opportunities for studying HCV infection [10] . Moreover, we have previously characterized -for the first time -enveloped HCV particles in the serum of chronic hepatitis C patients, so-called HCVsp [11] , thanks to unique monoclonal antibody (mAb) D32.10 which recognizes a highly conserved discontinuous antigenic determinant (E1: 297-306, E2: 480-494 and E2: 613-621) expressed on the surface of HCVsp from the main genotypes: 1a, 1b, 2a and 3a [12] . The availability of such systems prompted us to characterize the HCV RNA-containing particles released by primary cultures derived from in vivo HCV-infected cirrhotic human hepatocytes.
Materials and Methods

Isolation and Culture of in vivo HCV-Infected Human
Hepatocytes HCV-infected human hepatocytes were isolated as previously described [10] from liver surgical biopsies of 3 different cirrhotic patients (informed consent was obtained from patients): two of genotype 1b (P1 and P2) and one of genotype 2b (P3). Cells were seeded at a density of 50,000 cells/cm 2 in William's E medium containing 10% fetal bovine serum (FBS from Gibco BRL, Burlington, Ont., Canada). After 4 h, the medium was replaced by fresh medium containing 10% human serum from HCV-negative donors, 4.5 ! 10 -5 M hydrocortisone and 1% dimethyl-sulfoxide. The supernatants collected from day 2 to day 7 after plating were clarified by centrifugation for 10 min at 20,000 g and stored at -80 ° . HCV particles from the three distinct liver cultures (P1, P2 and P3) were semi-purified from 50 ml of supernatants by two sequential ultracentrifugations at 210,000 g for 4 h at 4 ° in order to eliminate the cell culture medium as previously described [11] . The final HCV-enriched pellets (called VP1, VP2 and VP3, respectively) were resuspended in 1-2 ml of TNE buffer (20 m M Tris-HCl, pH 7.5, 100 m M NaCl, 1 m M EDTA) and stored at -80 ° as small aliquots. Protein concentration was determined by BCA protein assay (Sigma Aldrich, Germany).
Purification of HCV Particles by Successive Ultracentrifugation Steps
Sedimentation Analysis: Buoyant Density Determination in Sucrose Gradients
To study the physicochemical properties of liver-derived HCV particles, each purified viral preparation (VP1, VP2 or VP3) was subjected to isopycnic centrifugation (200,000 g for 48 h at 4 ° ) in a sucrose density gradient (10-60% w/w) in the SW41 rotor of a Beckman centrifuge. Fractions (0.6 ml) were collected from the bottom of the tube, and the density of each was determined by refractometry. HCV-RNA content was assessed by branched DNA (b-DNA) technique and E1E2 antigenic reactivity analyzed by ELISA and Western blotting using the mAb D32.10.
HCV RNA Quantification
The quantification of HCV RNA in each of the different viral preparations (VP1, VP2 or VP3) as well as in the fractions from 3 distinct sucrose gradients was performed using the third generation of the b-DNA nucleic acid probe test (VERSANT HCV RNA 3.0 Assay; Bayer Diagnostics, Berkeley, Calif., USA). The assay required a sample volume of 50 l. The lower and upper detection limits were 2.5 ! 10 3 and 4.0 ! 10 7 copies/ml, respectively, as mentioned by the manufacturer. The final detection was performed in a semiautomated Bayer System 340 b-DNA analyzer.
E1E2 Antigenic Titration by Indirect ELISA E1E2 antigenic activity was determined as previously described [12] . Polyvinyl plates (Maxisorb, Nunc) were coated with the HCV final pellets VP1, VP2 or VP3 (from 6.25 to 200 g of protein/ml) or the fractions from sucrose gradients (dilution 1/5). The saturation was performed with TNB (20 m M Tris-HCl, pH 7.5, 100 m M NaCl) containing 5% bovine serum albumin. After four washings with TNB, the anti-E1E2/D32.10 mAb (5 g/ml) was added and incubated at 37 ° for 2 h. The bound antibody was then detected with horseradish peroxidase (HRP)-conjugated anti-mouse immunoglobulins (1/5,000 Immunotech), and orthophenylenediamine as substrate. The reaction was stopped by adding HCl 2 N and the optical density was read at 490 nm. The results were considered as positive (P) when superior to the cutoff, corresponding to the mean of negative (N) controls multiplied by 2.1, i.e. P/N ratio 1 2.1.
Western Blot Analysis
HCV envelope (E1 and E2) and core proteins were detected by immunoblotting using the mAb D32.10 [12] and rabbit polyclonal anti-core antibodies (C3, US Biological), respectively. Six micrograms of protein of each final HCV-enriched pellet (VP1, VP2 or VP3) and 10 g of different fractions from sucrose gradients were applied for the E1E2 detection. VP1, VP2 or VP3 were used to detect the core proteins. SDS-PAGE on 10% gel was performed under nonreducing and reducing conditions (2% SDS 8 5% 2 ␤ -mercaptoethanol) [11, 12] . After protein transfer onto polyvinylidene difluoride membranes, the mAb D32.10 (5 g/ml) or C3 polyclonal antibodies (1 g/ml) diluted in 50% normal human serum were added as primary antibodies. In the revelation phase, HRP-conjugated anti-mouse (1/5,000 Immunotech) or anti-rabbit (1/10,000 Immunotech) IgG F(ab )2 fragments were used, and the blots were revealed with an enhanced chemiluminescence detection system (ECL Plus system, Amersham Biosciences).
Immunohistochemistry
Hepatocytes isolated from two normal livers as negative controls (HCV-) and from two HCV-infected cirrhotic livers (HCV+) corresponding to VP2 (genotype 1b) and VP3 (genotype 2b) were used for immunohistochemistry. Cells were seeded at a density of 50,000 cells/cm 2 and grown in four-well chamber slides (LaB-Tek, Brands Products). At day 3, cells were fixed with paraformaldehyde (2% PFA in PBS) for 15 min at room temperature, washed threefold with PBS and stored at -80 ° until use. Immunostaining was performed using the Dakocytomation Envision dual link system HRP kit (Dako, Denmark). After permeabilization of cells with 0.1% saponine in PBS for 30 min at room temperature, and incubation with endogenous enzyme block for 10 min at room temperature, cells were incubated for 30 min with primary antibodies: the anti-E1E2/D32.10 mAb (2.5 g/ml) or the anti-E2/D4.12.9 mAb (1 g/ml) or mAb to HCV core antigen (clone 11-B3, C8A216M, Biodesign International; 20 g/ml). Revelation was then performed by incubation with 3.3-diaminobenzidine (DAB+) substrate-chromogen for 5-10 min. The brown-colored precipitate at the antigen site was observed by light microscopy.
Results
Expression of the E1E2/D32.10 Epitope on the HCV RNA-Containing Particles Released by Human Hepatocytes Derived from HCV-Infected Cirrhotic Livers
HCV particles released from primary cultures of human hepatocytes were semi-purified by sequential ultracentrifugation from supernatants collected on day 3 after seeding. This way, cellular material (debris) and proteins present in the culture medium were removed, and the pellet subjected to analysis represented HCV particle-enriched material. Three viral preparations (VPs) were obtained from three different patients: two of genotype 1b (VP1 and VP2) and one of genotype 2b (VP3). Their protein concentration was between 2 and 9.3 mg/ml, and their HCV RNA content between 2 ! 10 6 and 3.7 ! 10 7 copies/ml (or 4 ! 10 5 and 7 ! 10 6 IU/ml), corresponding to around 10 6 -10 7 copies of HCV RNA per mg of protein ( table 1 ) .
The HCV E1E2 antigenic activity of VP1, VP2 and VP3 was analyzed by indirect ELISA. The titration curve was established between 6.25 and 200 g of protein per ml ( fig. 1 A) . The E1E2 reactivity decreased linearly from 200 to 12.5 g/ml. VP3 seemed to exhibit the strongest E1E2 reactivity. The limit of positivity was around 10 g/ml for VP1 and ^ 5 g/ml for VP2 and VP3, which corresponded to 1-5 ! 10 4 copies of HCV RNA. To confirm the expression of E1 and E2 glycoproteins, VP1, VP2 and VP3 were subjected to SDS-PAGE and Western blot using the mAb D32.10. As shown in figure 1 B, both E1 (31 kDa) and E2 (60-68 kDa) proteins were clearly detected in the three HCV preparations. We noticed that there is good correlation between ELISA and Western blot techniques for the detection of E1E2 antigen (VP1 ! VP2 ! VP3), and more interesting between the E1E2 reactivity and the HCV RNA content ( table 1 ) . In addition, these results confirm that D32.10 detected the E1 and E2 proteins present in HCV particles obtained from genotype 2 as well as genotype 1 samples [11, 12] . In order to determine whether these HCV particles contained core proteins, Western blot analysis was performed using rabbit polyclonal anticore antibodies C3. As shown in figure 1 C, the monomeric HCV core protein of 25 kDa was only faintly detected in VP3 and not detectable in VP1, while a band at 50 kDa was clearly observed in VP3, and a strong reactivity was visualized at 75 kDa in VP1. Thus, it was difficult to conclude that these secreted particles contained core. In contrast, VP2 clearly expressed the HCV core protein of 25 kDa, as well as oligomeric forms at 50, 75 and 150 kDa, as already described for serum-derived HCV particles [HCVsp, 11 ] . This confirms a great molecular heterogeneity of core proteins even under reduc- ing conditions in liver-derived HCV particles, as in HCVsp [11] . These results strongly suggest that VP2 corresponds to complete HCV virions released from infected hepatocytes in culture supernatant.
The density distribution of liver-derived HCV particles (VP1, VP2 and VP3) was then analyzed by isopycnic centrifugation in a sucrose density gradient (10-60%; fig. 2 A-C, respectively). For VP1 ( fig. 2 A, panel a) , one major E1E2/D32.10-positive population with a density between 1.15-1.25 g/ml was observed with a peak of HCV RNA in fractions 11 and 12 containing 1.4 ! 10 5 and 3.3 ! 10 4 copies/ml, respectively, i.e. approximately 2 ! 10 5 copies of HCV RNA/ml in both fractions. For VP2 ( fig. 2 B, panel a) and VP3 ( fig. 2 C, panel a) , a narrow E1E2/D32.10 peak was observed between 1.15 and 1.21 g/ml and 1.15 and 1.18 g/ml, respectively. Fraction 12 (VP2; fig. 2 B, panel a) and fraction 11 (VP3; fig. 2 C, panel a) contained 3.8 ! 10 4 and 3.3 ! 10 4 copies of HCV RNA/ml, respectively. Selected fractions from sucrose gradients for each viral preparation (VP1, VP2 or VP3) were analyzed by immunoblotting using the mAb D32.10 under nonreducing (NR) and reducing (R) conditions ( fig. 2 A-C, panels b) . In R conditions (lower panels b), the monomeric forms of E1 and E2 glycoproteins were maximally detected in fractions 11 and 12 for VP1 ( fig. 2 A, panel b) , 11, 12 and 13 for VP2 ( fig. 2 B,  panel b) , and 10 and 11 for VP3 ( fig. 2 C, panel b) , corresponding to peaks in ELISA ( fig. 2 A-C, panels a) . In NR conditions, only high molecular weight bands ( 6 200 kDa) were observed, likely representing homo-heterodimeric forms of disulfide-bonded E1E2 envelope complexes ( fig. 2 A-C, higher panels b) . In figure 2 A, panel b, HCV-enriched pellet before sedimentation analysis was included as a positive control in the first lane. There is still a good correlation between the maximal detection of E1E2 envelope complexes and the presence of HCV RNA. All these signals are specific for HCV since no significant signal for both E1E2 in ELISA (P/N ! 2.1, fig. 2 D) and HCV RNA in real time RT-PCR ( ! 10 copies/ml, not shown) was detected all along the gradient when HCV-negative control preparation was analyzed in parallel. These results show that the HCV RNA-pos- (5 g) and selected fractions (10 g per lane) from the sucrose gradient (cf. panels a ) were subjected to 10% SDS-PAGE under NR or R conditions. The HCV E1 and E2 proteins were detected using the mAb D32.10, and blots were developed with an enhanced chemiluminescence detection system (ECL plus system, Amersham Biosciences). Molecular weights of HCV-specific proteins were expressed in kDa and are indicated on the right of the gels. Negative control (HCV-; D ) was obtained from noninfected liver and analyzed in a sucrose density gradient as in figure 2A-C. HCV RNA was tested in each fraction by quantitative real-time RT-PCR (detection limit = 10 copies/ml) and found negative all along the gradient ( ! 10 copies/ml, not shown). itive population released by human hepatocytes derived from HCV-infected cirrhotic livers (or HCV-lp) expresses the E1E2 epitope defined by the mAb D32.10 and sediments at a density of 1.15-1.25 g/ml in a sucrose density gradient.
Expression of the E1E2/D32.10 Epitope together with E2 and Core Antigens in Primary Cultured HCV-Infected Hepatocytes
In control noninfected (HCV-) hepatocytes ( fig. 3 A-D, panels a), no or very low background was observed in the absence (control, fig. 3 A) as well as in the presence of relevant primary antibodies (anti-E1E2/D32.10, fig. 3 B; anti-E2/D4.12.9, fig. 3 C, and anti-core, fig. 3 D) , even if some differences in brightness/contrast in the images could be observed. The results presented in figure 3 A-D, panels b, were obtained with hepatocytes derived from the HCV-infected cirrhotic liver (HCV+) corresponding to VP2 of genotype 1b. A very strong specific staining with a cytoplasmic localization was observed in the presence of either the mAb D32.10 ( fig. 3 B, panel b) or the mAb D4.12.9 ( fig. 3 C, panel b) . This demonstrates the expression of both E1E2 and E2 epitopes defined by each of these mAbs in HCV-infected hepatocytes from cirrhotic patients. Similar results for E1E2 (mAb D32.10) and E2 (mAb D4.12.9) were obtained with hepatocytes derived from the HCV-infected cirrhotic liver corresponding to VP3 of genotype 2b (results not shown). HCV core antigen was also clearly detected in the HCVinfected hepatocytes corresponding to VP2 of genotype 1b, as shown in figure 3 D, panel b . However, the mAb to HCV core antigen from Biodesign (recombinant HCV core antigen of genotype 1b as immunogen) used here did not react with hepatocytes derived from the HCV-infected cirrhotic liver corresponding to VP3 of genotype 2b (results not shown). These results support that the E1E2 . B Anti-E1E2/D32.10 mAb (2.5 g/ml). C Anti-E2/D4.12.9 mAb (1 g/ml). D Anti-core mAb (clone 11-B3, Biodesign International; 20 g/ml). The Dakocytomation Envision dual link system HRP kit (Dako, Denmark) was used for the revelation according to the manufacturer's instructions. The browncolored precipitate was observed by light microscopy.
